Circulating tumor DNA as a biomarker in metastatic colorectal cancer

Iris van't Erve

doi:10.33540/936

Circulating tumor DNA as a biomarker in metastatic colorectal cancer

Iris van't Erve

Research output: Thesis › Doctoral thesis 2 (Research NOT UU / Graduation UU)

Abstract

This thesis aimed to investigate the clinical applicability of liquid biopsy circulating tumor DNA (ctDNA) in the disease management of patients with metastatic colorectal cancer (mCRC). The results from this thesis have highlighted the advantages of ctDNA assessment as a promising liquid biopsy analyte and biomarker in patients with mCRC, but also provided a reality check for its clinical validity by emphasizing the importance of the right analytical approach per clinical application. Potential clinical applications of ctDNA could be divided into four groups; diagnosis, prediction, prognosis and response monitoring, of which the last three were investigated for patients with mCRC.

Original language	English
Awarding Institution	University Medical Center (UMC) Utrecht
Supervisors/Advisors	Meijer, Gerrit, Primary supervisor Punt, Kees, Supervisor Fijneman, Remond J A, Co-supervisor
Award date	17 May 2022
Publisher	Utrecht University
Print ISBNs	978-94-6458-180-5
DOIs	https://doi.org/10.33540/936
Publication status	Published - 17 May 2022
Externally published	Yes

Keywords

Liquid biopsy
circulating tumor DNA
cell-free DNA
colorectal cancer

Access to Document

10.33540/936

thesisiris van t erve - 624e2119b8b4fFinal published version, 129 MB

https://dspace.library.uu.nl/handle/1874/416603

Cite this

@phdthesis{108c6d53a8124d48b4150ac82910541f,

title = "Circulating tumor DNA as a biomarker in metastatic colorectal cancer",

abstract = "This thesis aimed to investigate the clinical applicability of liquid biopsy circulating tumor DNA (ctDNA) in the disease management of patients with metastatic colorectal cancer (mCRC). The results from this thesis have highlighted the advantages of ctDNA assessment as a promising liquid biopsy analyte and biomarker in patients with mCRC, but also provided a reality check for its clinical validity by emphasizing the importance of the right analytical approach per clinical application. Potential clinical applications of ctDNA could be divided into four groups; diagnosis, prediction, prognosis and response monitoring, of which the last three were investigated for patients with mCRC.",

keywords = "Liquid biopsy, circulating tumor DNA, cell-free DNA, colorectal cancer",

author = "{van't Erve}, Iris",

year = "2022",

month = may,

day = "17",

doi = "10.33540/936",

language = "English",

isbn = "978-94-6458-180-5",

publisher = "Utrecht University",

type = "Doctoral thesis 2 (Research NOT UU / Graduation UU)",

school = "UMC Utrecht",

}

TY - THES

T1 - Circulating tumor DNA as a biomarker in metastatic colorectal cancer

AU - van't Erve, Iris

PY - 2022/5/17

Y1 - 2022/5/17

N2 - This thesis aimed to investigate the clinical applicability of liquid biopsy circulating tumor DNA (ctDNA) in the disease management of patients with metastatic colorectal cancer (mCRC). The results from this thesis have highlighted the advantages of ctDNA assessment as a promising liquid biopsy analyte and biomarker in patients with mCRC, but also provided a reality check for its clinical validity by emphasizing the importance of the right analytical approach per clinical application. Potential clinical applications of ctDNA could be divided into four groups; diagnosis, prediction, prognosis and response monitoring, of which the last three were investigated for patients with mCRC.

AB - This thesis aimed to investigate the clinical applicability of liquid biopsy circulating tumor DNA (ctDNA) in the disease management of patients with metastatic colorectal cancer (mCRC). The results from this thesis have highlighted the advantages of ctDNA assessment as a promising liquid biopsy analyte and biomarker in patients with mCRC, but also provided a reality check for its clinical validity by emphasizing the importance of the right analytical approach per clinical application. Potential clinical applications of ctDNA could be divided into four groups; diagnosis, prediction, prognosis and response monitoring, of which the last three were investigated for patients with mCRC.

KW - Liquid biopsy

KW - circulating tumor DNA

KW - cell-free DNA

KW - colorectal cancer

U2 - 10.33540/936

DO - 10.33540/936

M3 - Doctoral thesis 2 (Research NOT UU / Graduation UU)

SN - 978-94-6458-180-5

PB - Utrecht University

ER -

Circulating tumor DNA as a biomarker in metastatic colorectal cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this